# BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

> **NCT04969861** · PHASE2,PHASE3 · TERMINATED · sponsor: **Nektar Therapeutics** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer

## Interventions

- **DRUG:** Bempegaldesleukin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04969861
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-09
- **Primary completion:** 2022-04-22
- **Final completion:** 2022-04-22
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36.
- **Last updated:** 2023-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969861, "BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04969861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*